Logo image of JNJ.DE

JOHNSON & JOHNSON (JNJ.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:JNJ - US4781601046 - Common Stock

174.98 EUR
-0.96 (-0.55%)
Last: 12/23/2025, 7:00:00 PM
Fundamental Rating

5

Overall JNJ gets a fundamental rating of 5 out of 10. We evaluated JNJ against 54 industry peers in the Pharmaceuticals industry. While JNJ belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. JNJ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year JNJ was profitable.
In the past year JNJ had a positive cash flow from operations.
In the past 5 years JNJ has always been profitable.
JNJ had a positive operating cash flow in each of the past 5 years.
JNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFJNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

1.2 Ratios

Looking at the Return On Assets, with a value of 13.03%, JNJ belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
The Return On Equity of JNJ (31.69%) is better than 77.78% of its industry peers.
The Return On Invested Capital of JNJ (14.68%) is better than 75.93% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JNJ is in line with the industry average of 13.79%.
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROIC 14.68%
ROA(3y)12.79%
ROA(5y)11.65%
ROE(3y)31.38%
ROE(5y)29.12%
ROIC(3y)15.41%
ROIC(5y)14.48%
JNJ.DE Yearly ROA, ROE, ROICJNJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

JNJ has a better Profit Margin (27.26%) than 88.89% of its industry peers.
JNJ's Profit Margin has declined in the last couple of years.
JNJ's Operating Margin of 27.00% is fine compared to the rest of the industry. JNJ outperforms 75.93% of its industry peers.
In the last couple of years the Operating Margin of JNJ has grown nicely.
JNJ has a Gross Margin of 68.14%. This is comparable to the rest of the industry: JNJ outperforms 50.00% of its industry peers.
In the last couple of years the Gross Margin of JNJ has remained more or less at the same level.
Industry RankSector Rank
OM 27%
PM (TTM) 27.26%
GM 68.14%
OM growth 3Y0.33%
OM growth 5Y3.14%
PM growth 3Y-15.79%
PM growth 5Y-2.98%
GM growth 3Y-0.56%
GM growth 5Y0.76%
JNJ.DE Yearly Profit, Operating, Gross MarginsJNJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

5

2. Health

2.1 Basic Checks

JNJ has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for JNJ remains at a similar level compared to 1 year ago.
JNJ has less shares outstanding than it did 5 years ago.
JNJ has a worse debt/assets ratio than last year.
JNJ.DE Yearly Shares OutstandingJNJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
JNJ.DE Yearly Total Debt VS Total AssetsJNJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

JNJ has an Altman-Z score of 4.77. This indicates that JNJ is financially healthy and has little risk of bankruptcy at the moment.
JNJ's Altman-Z score of 4.77 is fine compared to the rest of the industry. JNJ outperforms 72.22% of its industry peers.
The Debt to FCF ratio of JNJ is 2.34, which is a good value as it means it would take JNJ, 2.34 years of fcf income to pay off all of its debts.
JNJ has a better Debt to FCF ratio (2.34) than 77.78% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that JNJ is somewhat dependend on debt financing.
JNJ has a Debt to Equity ratio of 0.55. This is comparable to the rest of the industry: JNJ outperforms 51.85% of its industry peers.
Even though the debt/equity ratio score it not favorable for JNJ, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Altman-Z 4.77
ROIC/WACC1.5
WACC9.79%
JNJ.DE Yearly LT Debt VS Equity VS FCFJNJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

JNJ has a Current Ratio of 1.07. This is a normal value and indicates that JNJ is financially healthy and should not expect problems in meeting its short term obligations.
JNJ's Current ratio of 1.07 is on the low side compared to the rest of the industry. JNJ is outperformed by 70.37% of its industry peers.
A Quick Ratio of 0.80 indicates that JNJ may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.80, JNJ is doing worse than 62.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.8
JNJ.DE Yearly Current Assets VS Current LiabilitesJNJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.37% over the past year.
The Earnings Per Share has been growing slightly by 2.85% on average over the past years.
Looking at the last year, JNJ shows a small growth in Revenue. The Revenue has grown by 5.08% in the last year.
Measured over the past years, JNJ shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)1.37%
EPS 3Y0.64%
EPS 5Y2.85%
EPS Q2Q%15.7%
Revenue 1Y (TTM)5.08%
Revenue growth 3Y4.1%
Revenue growth 5Y1.6%
Sales Q2Q%6.77%

3.2 Future

JNJ is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.
JNJ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.29% yearly.
EPS Next Y9.83%
EPS Next 2Y7.97%
EPS Next 3Y7.73%
EPS Next 5Y7.68%
Revenue Next Year5.6%
Revenue Next 2Y5.44%
Revenue Next 3Y5.28%
Revenue Next 5Y5.29%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JNJ.DE Yearly Revenue VS EstimatesJNJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
JNJ.DE Yearly EPS VS EstimatesJNJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

3

4. Valuation

4.1 Price/Earnings Ratio

JNJ is valuated rather expensively with a Price/Earnings ratio of 19.86.
JNJ's Price/Earnings ratio is in line with the industry average.
JNJ's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.50.
With a Price/Forward Earnings ratio of 17.71, JNJ is valued on the expensive side.
JNJ's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.93. JNJ is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 19.86
Fwd PE 17.71
JNJ.DE Price Earnings VS Forward Price EarningsJNJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of JNJ is on the same level as its industry peers.
JNJ's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 25.35
EV/EBITDA 15.79
JNJ.DE Per share dataJNJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.02
PEG (5Y)6.97
EPS Next 2Y7.97%
EPS Next 3Y7.73%

5

5. Dividend

5.1 Amount

JNJ has a Yearly Dividend Yield of 2.47%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 1.85, JNJ pays a bit more dividend than its industry peers.
JNJ's Dividend Yield is a higher than the S&P500 average which is at 1.87.
Industry RankSector Rank
Dividend Yield 2.47%

5.2 History

On average, the dividend of JNJ grows each year by 9.24%, which is quite nice.
Dividend Growth(5Y)9.24%
Div Incr Years6
Div Non Decr Years6
JNJ.DE Yearly Dividends per shareJNJ.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4 5

5.3 Sustainability

48.70% of the earnings are spent on dividend by JNJ. This is a bit on the high side, but may be sustainable.
The dividend of JNJ is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP48.7%
EPS Next 2Y7.97%
EPS Next 3Y7.73%
JNJ.DE Yearly Income VS Free CF VS DividendJNJ.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B
JNJ.DE Dividend Payout.JNJ.DE Dividend Payout, showing the Payout Ratio.JNJ.DE Dividend Payout.PayoutRetained Earnings

JOHNSON & JOHNSON

FRA:JNJ (12/23/2025, 7:00:00 PM)

174.98

-0.96 (-0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-14 2025-10-14/bmo
Earnings (Next)01-21 2026-01-21/amc
Inst Owners74.99%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap421.58B
Revenue(TTM)92.15B
Net Income(TTM)25.12B
Analysts75.63
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.47%
Yearly Dividend4.19
Dividend Growth(5Y)9.24%
DP48.7%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.42%
Min EPS beat(2)0.55%
Max EPS beat(2)2.3%
EPS beat(4)4
Avg EPS beat(4)2.37%
Min EPS beat(4)0.55%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.79%
EPS beat(12)11
Avg EPS beat(12)3.6%
EPS beat(16)14
Avg EPS beat(16)3.08%
Revenue beat(2)2
Avg Revenue beat(2)1.48%
Min Revenue beat(2)0.03%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.55%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.34%
Revenue beat(12)7
Avg Revenue beat(12)-2.01%
Revenue beat(16)7
Avg Revenue beat(16)-8.34%
PT rev (1m)0.33%
PT rev (3m)14.31%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)-1.76%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)0.03%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.39%
Valuation
Industry RankSector Rank
PE 19.86
Fwd PE 17.71
P/S 5.39
P/FCF 25.35
P/OCF 20.53
P/B 6.27
P/tB N/A
EV/EBITDA 15.79
EPS(TTM)8.81
EY5.03%
EPS(NY)9.88
Fwd EY5.65%
FCF(TTM)6.9
FCFY3.94%
OCF(TTM)8.52
OCFY4.87%
SpS32.45
BVpS27.92
TBVpS-6.17
PEG (NY)2.02
PEG (5Y)6.97
Graham Number74.39
Profitability
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROCE 17.53%
ROIC 14.68%
ROICexc 16.82%
ROICexgc 69.32%
OM 27%
PM (TTM) 27.26%
GM 68.14%
FCFM 21.27%
ROA(3y)12.79%
ROA(5y)11.65%
ROE(3y)31.38%
ROE(5y)29.12%
ROIC(3y)15.41%
ROIC(5y)14.48%
ROICexc(3y)18.76%
ROICexc(5y)17.88%
ROICexgc(3y)74.12%
ROICexgc(5y)78.04%
ROCE(3y)18.6%
ROCE(5y)17.28%
ROICexgc growth 3Y1.2%
ROICexgc growth 5Y-0.66%
ROICexc growth 3Y3.58%
ROICexc growth 5Y3.41%
OM growth 3Y0.33%
OM growth 5Y3.14%
PM growth 3Y-15.79%
PM growth 5Y-2.98%
GM growth 3Y-0.56%
GM growth 5Y0.76%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Debt/EBITDA 1.36
Cap/Depr 62.36%
Cap/Sales 5%
Interest Coverage 250
Cash Conversion 75.02%
Profit Quality 78.02%
Current Ratio 1.07
Quick Ratio 0.8
Altman-Z 4.77
F-Score5
WACC9.79%
ROIC/WACC1.5
Cap/Depr(3y)59.5%
Cap/Depr(5y)54.84%
Cap/Sales(3y)5.11%
Cap/Sales(5y)4.8%
Profit Quality(3y)96.25%
Profit Quality(5y)104.12%
High Growth Momentum
Growth
EPS 1Y (TTM)1.37%
EPS 3Y0.64%
EPS 5Y2.85%
EPS Q2Q%15.7%
EPS Next Y9.83%
EPS Next 2Y7.97%
EPS Next 3Y7.73%
EPS Next 5Y7.68%
Revenue 1Y (TTM)5.08%
Revenue growth 3Y4.1%
Revenue growth 5Y1.6%
Sales Q2Q%6.77%
Revenue Next Year5.6%
Revenue Next 2Y5.44%
Revenue Next 3Y5.28%
Revenue Next 5Y5.29%
EBIT growth 1Y2.89%
EBIT growth 3Y4.44%
EBIT growth 5Y4.79%
EBIT Next Year30.64%
EBIT Next 3Y13.37%
EBIT Next 5Y8.85%
FCF growth 1Y24.53%
FCF growth 3Y0.14%
FCF growth 5Y-0.08%
OCF growth 1Y19.36%
OCF growth 3Y1.2%
OCF growth 5Y0.72%

JOHNSON & JOHNSON / JNJ.DE FAQ

Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?

ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE.


What is the valuation status for JNJ stock?

ChartMill assigns a valuation rating of 3 / 10 to JOHNSON & JOHNSON (JNJ.DE). This can be considered as Overvalued.


What is the profitability of JNJ stock?

JOHNSON & JOHNSON (JNJ.DE) has a profitability rating of 7 / 10.


What is the financial health of JOHNSON & JOHNSON (JNJ.DE) stock?

The financial health rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10.


How sustainable is the dividend of JOHNSON & JOHNSON (JNJ.DE) stock?

The dividend rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10 and the dividend payout ratio is 48.7%.